tranexamic acid has been researched along with Autosomal Hemophilia A in 78 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia." | 7.79 | Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013) |
| "Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders." | 7.71 | Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002) |
| "We examined whether the clot stability in hemophiliacs could be improved by treatment with tranexamic acid (TXA) in combination with recombinant factor VIII (rFVIII)." | 6.73 | Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. ( Christiansen, K; Hvas, AM; Ingerslev, J; Norengaard, L; Sørensen, B; Sørensen, HT, 2007) |
| " The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders." | 4.98 | Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "The use of a standardized protocol increased the use of tranexamic acid, with a nonstatistically significant reduction in procedural bleeding rate." | 4.12 | Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders. ( Bourassa, M; Champagne, PA; Cloutier, S; Demers, C; Desjardins, MP; Néron, H; Pelland-Marcotte, MC; Singbo, NU, 2022) |
| " In postpartal period an excellent control of bleeding was obtained by regularly administering FVIII concentrate for several days as well by concomitant use of tranexamic acid and oral contraceptive pills in the next 6 weeks." | 3.85 | Pregnancy and delivery in a woman with severe haemophilia A. ( Antic, DA; Bodrozic, JN; Djunic, IS; Lekovic, DR; Miljic, PS; Mitrovic, MM; Petronijevic, MA; Petronijevic-Vrzic, SM, 2017) |
| "A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia." | 3.79 | Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013) |
| "Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A." | 3.75 | Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. ( Günaldi, M; Helvaci, A; Kiskaç, M; Küçükkaya, RD; Yildirim, ND, 2009) |
| "Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders." | 3.71 | Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002) |
| "We examined whether the clot stability in hemophiliacs could be improved by treatment with tranexamic acid (TXA) in combination with recombinant factor VIII (rFVIII)." | 2.73 | Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. ( Christiansen, K; Hvas, AM; Ingerslev, J; Norengaard, L; Sørensen, B; Sørensen, HT, 2007) |
| "Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management." | 2.72 | Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021) |
| "Sixteen patients with haemophilia who required dental scaling participated in this pilot study." | 2.71 | Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. ( Boyle, CA; Fiske, J; Lee, AP; Savidge, GF, 2005) |
| "Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors." | 2.70 | Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001) |
| "The bleeding was effectively controlled within 1 to 48 h in five of nine bleeding episodes." | 2.69 | Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. ( Angchaisuksiri, P; Chuansumrit, A; Hathirat, P; Isarangkura, P; Jorgensen, LN; Sriudomporn, N; Tanpowpong, K, 2000) |
| "A total of 59 participants with haemophilia undergoing dental extraction were involved." | 2.55 | Preventing perioperative bleeding in patients with inherited bleeding disorders. ( Beacher, N; Watterson, C, 2017) |
| "In people with haemophilia or other congenital bleeding disorders undergoing surgical interventions, haemostatic treatment is needed in order to correct the underlying coagulation abnormalities and minimise the bleeding risk." | 2.52 | Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. ( Coppola, A; Di Minno, MN; Tufano, A; Windyga, J; Yeung, C, 2015) |
| "Ninety-two hemophilia A patients who underwent total knee arthroplasty in our center were included." | 1.72 | Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors. ( Lv, SJ; Shen, SN; Tong, PJ; Wu, DX, 2022) |
| "Patients with severe haemophilia have impaired haemostatic response, delayed clot formation and fibrin clots that are vulnerable to fibrinolysis." | 1.62 | Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study. ( Bolbos, R; Bordet, JC; Brevet, M; Dargaud, Y; Enjolras, N; Janbain, M, 2021) |
| "To examine UK haemophilia centre registration patterns and current practice for UBD patients." | 1.62 | Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. ( Desborough, M; Downes, K; Evans, G; Gidley, G; Lowe, G; MacDonald, S; O'Donnell, JS; Obaji, S; Palmer, B; Pinto, F; Thomas, W, 2021) |
| "Acquired haemophilia A is a rare but important diagnosis, carrying a mortality rate of 22%." | 1.56 | ( Howden, WB; Kam, J; Leith, N; Singh, S, 2020) |
| "Approximately 50% of female carriers of hemophilia A have factor VIII (FVIII) levels below 0." | 1.56 | Hemophilia A in Females: Considerations for Clinical Management. ( Boukouvala, A; Bryant, P; McDaniel, J; Nance, D, 2020) |
| "This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results." | 1.51 | Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast). ( Adjambri, E; Eeckhoudt, S; Hermans, C; Lambert, C; Lobet, S; Meité, ND; Sanogo, I, 2019) |
| "Thirty-four patients with haemophilia A undergoing 24 TKA and 18 THA were evaluated in this retrospective study (No." | 1.51 | Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia. ( Huang, Q; Huang, ZY; Ma, J; Pei, FX; Shen, B; Zeng, HJ; Zhou, ZK, 2019) |
| "In mice, induced and congenital hemophilia models were combined with fibrinolytic attenuation achieved either genetically or pharmacologically (tranexamic acid [TXA])." | 1.48 | Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents. ( Bojko, B; Flick, MJ; Goryńska, PZ; Goryński, K; Knudsen, T; Ley, CD; Olsen, LH; Stagaard, R, 2018) |
| "Haemophilia is characterised by defective thrombin generation, reduced clot stability and spontaneous bleeding." | 1.40 | An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. ( Bevan, DH; Foley, JH; Rea, CJ; Sørensen, B, 2014) |
| "Healthy volunteers (N = 5) and haemophilia inhibitor patients (N = 6) were enrolled in a prospective case crossover design." | 1.40 | Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. ( Bjørnsen, S; Holme, PA; Pripp, AH; Rea, CJ; Sørensen, B; Tjønnfjord, GE; Tran, HT; Ueland, T, 2014) |
| "The management of bleeding in haemophilia patients with inhibitors can be challenging when using monotherapy with either activated prothrombin complex concentrate (APCC) or recombinant activated FVII (rFVIIa) fail." | 1.38 | Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. ( Holme, PA; Holmström, M; Tran, HT, 2012) |
| "Defective hemostasis in haemophilia patients with FVIII inhibitors results in a dramatic decrease in thrombin generation forming unstable fibrin clots that are susceptible to fibrinolyisis." | 1.37 | Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. ( Bevan, D; Dai, L; Mitchell, M; Rangarajan, S; Sørensen, B, 2011) |
| "However, thrombosis has occurred in three of 12 such patients." | 1.35 | Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. ( Bar-Zakay, B; Horowitz, Z; Korianski, Y; Livnat, T; Mor, Y; Salomon, O; Seligsohn, U; Tamarin, I; Winckler, H, 2009) |
| "Dental extraction in hemophiliacs is associated with a high risk of bleeding." | 1.33 | Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). ( Berthier, AM; De Mello, G; Frachon, X; Garnier, J; Hourdin-Eude, S; Lejeune, S; Mézière, X; Pommereuil, M; Quéro, J, 2005) |
| "Acquired haemophilia was diagnosed following detailed investigation of a post-partum haemorrhage unresponsive to standard management." | 1.31 | Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage. ( Howland, EJ; Keay, SD; Lumley, M; Palmer, J, 2002) |
| "Two patients with hemophilia A complicated with high-titer alloantibodies have been treated by repeated infusions of microgram quantities of pure human Factor VIIa." | 1.27 | Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. ( Hedner, U; Kisiel, W, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (26.92) | 18.7374 |
| 1990's | 4 (5.13) | 18.2507 |
| 2000's | 17 (21.79) | 29.6817 |
| 2010's | 26 (33.33) | 24.3611 |
| 2020's | 10 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Janbain, M | 1 |
| Enjolras, N | 1 |
| Bolbos, R | 1 |
| Brevet, M | 1 |
| Bordet, JC | 1 |
| Dargaud, Y | 1 |
| Shen, SN | 1 |
| Wu, DX | 1 |
| Lv, SJ | 1 |
| Tong, PJ | 1 |
| Champagne, PA | 1 |
| Bourassa, M | 1 |
| Desjardins, MP | 1 |
| Cloutier, S | 1 |
| Demers, C | 1 |
| Singbo, NU | 1 |
| Néron, H | 1 |
| Pelland-Marcotte, MC | 1 |
| Waberski, AT | 1 |
| Busack, C | 1 |
| d'Acoz, YD | 1 |
| Matisoff, AJ | 1 |
| Castle, D | 1 |
| Desborough, MJR | 1 |
| Kemp, M | 1 |
| Lowe, G | 2 |
| Thomas, W | 2 |
| Obaji, S | 2 |
| Huang, ZY | 1 |
| Huang, Q | 1 |
| Zeng, HJ | 1 |
| Ma, J | 1 |
| Shen, B | 1 |
| Zhou, ZK | 1 |
| Pei, FX | 1 |
| Bryant, P | 1 |
| Boukouvala, A | 1 |
| McDaniel, J | 1 |
| Nance, D | 1 |
| Marlière, C | 1 |
| Maindiaux, L | 1 |
| Lambert, C | 2 |
| Hermans, C | 2 |
| Howden, WB | 1 |
| Kam, J | 1 |
| Leith, N | 1 |
| Singh, S | 1 |
| Punt, MC | 1 |
| Waning, ML | 1 |
| Mauser-Bunschoten, EP | 2 |
| Kruip, MJHA | 1 |
| Eikenboom, J | 1 |
| Nieuwenhuizen, L | 1 |
| Makelburg, ABU | 1 |
| Driessens, MHE | 1 |
| Duvekot, JJ | 1 |
| Peters, M | 1 |
| Middeldorp, JM | 1 |
| Bloemenkamp, KWM | 1 |
| Schutgens, REG | 1 |
| Lely, AT | 1 |
| van Galen, KPM | 1 |
| Downes, K | 1 |
| Evans, G | 1 |
| Gidley, G | 1 |
| MacDonald, S | 1 |
| O'Donnell, JS | 1 |
| Palmer, B | 1 |
| Pinto, F | 1 |
| Desborough, M | 1 |
| Watterson, C | 1 |
| Beacher, N | 1 |
| Stagaard, R | 1 |
| Flick, MJ | 1 |
| Bojko, B | 1 |
| Goryński, K | 1 |
| Goryńska, PZ | 1 |
| Ley, CD | 1 |
| Olsen, LH | 1 |
| Knudsen, T | 1 |
| Lewandowski, B | 1 |
| Wojnar, J | 1 |
| Brodowski, R | 1 |
| Mucha, M | 1 |
| Czenczek-Lewandowska, E | 1 |
| Brzęcka, D | 1 |
| Bannow, BS | 1 |
| Konkle, BA | 1 |
| Meité, ND | 1 |
| Sanogo, I | 1 |
| Lobet, S | 1 |
| Adjambri, E | 1 |
| Eeckhoudt, S | 1 |
| Fisher, C | 1 |
| Mo, A | 1 |
| Warrillow, S | 1 |
| Smith, C | 1 |
| Jones, D | 1 |
| Rea, CJ | 2 |
| Foley, JH | 1 |
| Bevan, DH | 1 |
| Sørensen, B | 4 |
| Tran, HT | 2 |
| Bjørnsen, S | 1 |
| Ueland, T | 1 |
| Pripp, AH | 1 |
| Tjønnfjord, GE | 1 |
| Holme, PA | 2 |
| Koyama, T | 1 |
| Clerico, C | 1 |
| Benatar, M | 1 |
| Dumontier, C | 1 |
| Freeman, A | 1 |
| Coppola, A | 1 |
| Windyga, J | 2 |
| Tufano, A | 1 |
| Yeung, C | 1 |
| Di Minno, MN | 1 |
| Rath, A | 1 |
| Nakamura, L | 1 |
| van der Werf-Grohmann, N | 1 |
| Zieger, B | 1 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Rodriguez-Merchan, EC | 1 |
| Romero-Garrido, JA | 1 |
| Gomez-Cardero, P | 1 |
| Sagheer, S | 1 |
| Atkins, A | 1 |
| McRae, S | 1 |
| Stefanska-Windyga, E | 1 |
| Odnoczko, E | 1 |
| Baran, B | 1 |
| Czubak, G | 1 |
| Bodrozic, JN | 1 |
| Miljic, PS | 1 |
| Lekovic, DR | 1 |
| Petronijevic, MA | 1 |
| Antic, DA | 1 |
| Mitrovic, MM | 1 |
| Petronijevic-Vrzic, SM | 1 |
| Djunic, IS | 1 |
| Fuentes García, D | 1 |
| Ramírez Muñoz, G | 1 |
| Livnat, T | 1 |
| Tamarin, I | 1 |
| Mor, Y | 1 |
| Winckler, H | 1 |
| Horowitz, Z | 1 |
| Korianski, Y | 1 |
| Bar-Zakay, B | 1 |
| Seligsohn, U | 1 |
| Salomon, O | 1 |
| Günaldi, M | 1 |
| Helvaci, A | 1 |
| Yildirim, ND | 1 |
| Kiskaç, M | 1 |
| Küçükkaya, RD | 1 |
| Yilmaz, D | 1 |
| Akin, M | 1 |
| Ay, Y | 1 |
| Balkan, C | 1 |
| Celik, A | 1 |
| Ergün, O | 1 |
| Kavakli, K | 1 |
| Dai, L | 1 |
| Bevan, D | 1 |
| Rangarajan, S | 1 |
| Mitchell, M | 1 |
| Diplaris, KT | 1 |
| Karfis, EA | 1 |
| Ampatzidou, F | 1 |
| Ananiadou, OG | 1 |
| Vakalopoulou, S | 1 |
| Madesis, A | 1 |
| Asteri, T | 1 |
| Drossos, G | 1 |
| Holmström, M | 1 |
| Cakr, O | 1 |
| Kazancoğlu, HO | 1 |
| Ak, G | 1 |
| Zülfikar, B | 1 |
| Bajkin, BV | 1 |
| Rajic, NV | 1 |
| Vujkov, SB | 1 |
| Noble, S | 1 |
| Chitnis, J | 1 |
| Taparia, M | 1 |
| Cordingley, FT | 1 |
| Leahy, MF | 1 |
| Mannucci, PM | 1 |
| Frachon, X | 1 |
| Pommereuil, M | 1 |
| Berthier, AM | 1 |
| Lejeune, S | 1 |
| Hourdin-Eude, S | 1 |
| Quéro, J | 1 |
| Mézière, X | 1 |
| De Mello, G | 1 |
| Garnier, J | 1 |
| Lee, AP | 1 |
| Boyle, CA | 1 |
| Savidge, GF | 1 |
| Fiske, J | 1 |
| De Bels, D | 1 |
| Demeere, JL | 1 |
| Dugauquier, J | 1 |
| Louis, P | 1 |
| Van der Vorst, E | 1 |
| Coetzee, MJ | 1 |
| Schulman, S | 1 |
| Hvas, AM | 1 |
| Sørensen, HT | 1 |
| Norengaard, L | 1 |
| Christiansen, K | 1 |
| Ingerslev, J | 6 |
| Shankar, S | 1 |
| Lee, R | 1 |
| Hedner, U | 1 |
| Kisiel, W | 1 |
| Ikemura, K | 1 |
| Shirahata, A | 1 |
| Nakamura, T | 1 |
| Guillaume, M | 1 |
| Devos, R | 1 |
| Rizza, CR | 1 |
| Prinsley, P | 1 |
| Wood, M | 1 |
| Lee, CA | 1 |
| Waly, NG | 1 |
| Chuansumrit, A | 1 |
| Isarangkura, P | 1 |
| Angchaisuksiri, P | 1 |
| Sriudomporn, N | 1 |
| Tanpowpong, K | 1 |
| Hathirat, P | 1 |
| Jorgensen, LN | 1 |
| Tagariello, G | 1 |
| De Biasi, E | 1 |
| Gajo, GB | 1 |
| Risato, R | 1 |
| Radossi, P | 1 |
| Davoli, PG | 1 |
| Traldi, A | 1 |
| Odabaş, AR | 1 |
| Cetinkaya, R | 1 |
| Selçuk, Y | 1 |
| Kaya, H | 1 |
| Coşkun , U | 1 |
| Stubbs, M | 1 |
| Lloyd, J | 1 |
| Santagostino, E | 1 |
| Morfini, M | 1 |
| Rocino, A | 1 |
| Baudo, F | 2 |
| Scaraggi, FA | 1 |
| Gringeri, A | 1 |
| Howland, EJ | 1 |
| Palmer, J | 1 |
| Lumley, M | 1 |
| Keay, SD | 1 |
| Boulton, FE | 1 |
| Smith, A | 1 |
| Nilsson, IM | 1 |
| Mikaelsson, M | 1 |
| Vilhardt, H | 1 |
| Walter, H | 1 |
| Prentice, CR | 1 |
| Feldstedt, M | 1 |
| Sindet-Pedersen, S | 6 |
| Casdorph, DL | 1 |
| deCataldo, F | 1 |
| Landonio, G | 1 |
| Muti, G | 1 |
| Ramström, G | 2 |
| Blombäck, M | 2 |
| Verstraete, M | 1 |
| Stenbjerg, S | 3 |
| Prince, S | 1 |
| Pignanelli, M | 1 |
| Rota, L | 1 |
| Pignanelli, C | 1 |
| Vinckier, F | 1 |
| Vermylen, J | 1 |
| Peterson, J | 1 |
| Evans, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042] | 1,100 participants (Anticipated) | Observational | 2007-07-31 | Completed | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
10 reviews available for tranexamic acid and Autosomal Hemophilia A
| Article | Year |
|---|---|
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Delivery, Obstetric; Female; Hemophilia A; Hemor | 2021 |
Preventing perioperative bleeding in patients with inherited bleeding disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hemophilia A; Humans; Postoperativ | 2017 |
Inherited Bleeding Disorders in the Obstetric Patient.
Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia | 2018 |
[Treatment of acquired inhibitors of coagulation factors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antifibrinolytic Agents; Autoantibodies; Blood Coagulation F | 2014 |
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor VIIa; Hemophilia A; Hemophi | 2015 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Inhibitors of fibrinolysis in the treatment of haemophilia.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Hematuria; Hemophilia A; Humans; Surgical Procedures, Op | 1980 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
5 trials available for tranexamic acid and Autosomal Hemophilia A
| Article | Year |
|---|---|
Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Dental Care for Chronically Ill; Dental Scaling; Double | 2005 |
Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation; Drug Therapy, Combination; Factor VIII; Fibrinoly | 2007 |
Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions.
Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Child; Child, Preschool; Fac | 1995 |
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Child, Preschool; Disease Management; Fact | 2000 |
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi | 2001 |
63 other studies available for tranexamic acid and Autosomal Hemophilia A
| Article | Year |
|---|---|
Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Factor VIII; Hemophilia A; Hemos | 2021 |
Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blo | 2022 |
Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders.
Topics: Adult; Dentistry; Female; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Retrospective Studies | 2022 |
Massive Clot Formation Following FEIBA and Tranexamic Acid Administration in Postcardiopulmonary Bypass Hemorrhage.
Topics: Blood Coagulation Factors; Factor VIII; Hemophilia A; Hemorrhage; Humans; Tranexamic Acid | 2022 |
Outcomes and management of pregnancy in women with bleeding disorder of unknown cause.
Topics: Deamino Arginine Vasopressin; Female; Hemophilia A; Hemostatics; Humans; Postpartum Hemorrhage; Preg | 2022 |
Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthralgia; Arthroplasty, Replacement, | 2019 |
Hemophilia A in Females: Considerations for Clinical Management.
Topics: Adolescent; Aged; Chromosome Inversion; Deamino Arginine Vasopressin; Disease Management; Drug Subst | 2020 |
EHL-FIX in haemophilia B carriers with FIX deficiency.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Child; Factor IX; Female; Half-Life; Hemophilia A; Hemop | 2020 |
Topics: Aged, 80 and over; Airway Obstruction; Antifibrinolytic Agents; Cyclophosphamide; Glucocorticoids; H | 2020 |
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Topics: Anticoagulants; Female; Hemophilia A; Humans; Pregnancy; Tranexamic Acid; United Kingdom; Venous Thr | 2021 |
Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Topics: Animals; Antifibrinolytic Agents; Coagulants; Disease Models, Animal; Factor VIIa; Factor VIII; Fibr | 2018 |
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop | 2018 |
Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast).
Topics: Adolescent; Adult; Awareness; Cote d'Ivoire; Cross-Sectional Studies; Factor VIII; Female; Hemophili | 2019 |
Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Transfusion; Endometrial Neoplasms; Factor | 2013 |
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Drug Therapy, Combination; Factor VIIa; Factor VIII; Hem | 2014 |
Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Cros | 2014 |
Radial artery pseudoaneurysm: a rare complication after arthroscopic treatment of a volar wrist ganglion in a hemophilia patient.
Topics: Adult; Aneurysm, False; Antifibrinolytic Agents; Arthroscopy; Ganglion Cysts; Hemophilia A; Humans; | 2014 |
Acquired haemophilia A presenting at a District General Hospital.
Topics: Adrenal Cortex Hormones; Antifibrinolytic Agents; Blood Coagulation Factors; C-Reactive Protein; Dia | 2015 |
Acute "Tumour-like" Tongue Haematoma: The Challenge to Diagnose Haemophilia A.
Topics: Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Hemophilia A; Humans; Male; Or | 2015 |
Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies | 2016 |
Successful use of tranexamic acid in the management of haemophilic pseudotumour.
Topics: Abdomen; Aged; Animals; Antibodies, Neutralizing; Antifibrinolytic Agents; Coagulants; Cysts; Factor | 2016 |
Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors.
Topics: Adult; Antibodies, Neutralizing; Antifibrinolytic Agents; Blood Coagulation Factors; Coagulants; Dos | 2016 |
Pregnancy and delivery in a woman with severe haemophilia A.
Topics: Adult; Factor VIII; Female; Hemophilia A; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He | 2017 |
[Type A hemophilia in a man undergoing liver resection for metastasis: implications for anesthetic management].
Topics: Adenocarcinoma; Aged; Anesthesia, General; Blood Loss, Surgical; Colorectal Neoplasms; Deamino Argin | 2009 |
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Topics: Alleles; Blood Loss, Surgical; Factor VIIa; Factor XI; Factor XI Deficiency; Female; Hemophilia A; H | 2009 |
Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Blood Loss, Surgical; Coagulants; Coronary | 2009 |
A single centre experience in circumcision of haemophilia patients: Izmir protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Circumcision, Male; Factor I | 2010 |
Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
Topics: Adolescent; Adult; Aged; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Fibr | 2011 |
Acute type-a dissection in a patient with severe hemophilia A.
Topics: Acute Disease; Aortic Aneurysm; Aortic Dissection; Factor VIII; Hemophilia A; Humans; Male; Middle A | 2012 |
Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Coagulants; Hemophilia | 2012 |
Treatment of odontogenic large cysts in haemophiliac patients.
Topics: Antifibrinolytic Agents; Disease Management; Drug Administration Schedule; Epinephrine; Factor IX; F | 2012 |
Dental extraction in a hemophilia patient without factor replacement therapy: a case report.
Topics: Adult; Antifibrinolytic Agents; Bicuspid; Curettage; Dental Care for Chronically Ill; Dental Caries; | 2012 |
Case report: use of topical tranexamic acid to stop localised bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Hemophilia A; Hemorrhage; Humans; Male; Nipples; T | 2013 |
Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
Topics: Adult; Antifibrinolytic Agents; Autoantibodies; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male; | 2002 |
Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002).
Topics: Adolescent; Adult; Aged; Child; Clinical Protocols; Deamino Arginine Vasopressin; Dental Care for Ch | 2005 |
Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A.
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary | 2004 |
The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Dental Care for Chronically Ill | 2007 |
The onerous task of comparing treatments in inhibitor patients.
Topics: Blood Coagulation; Clinical Trials as Topic; Cohort Studies; Factor VII; Factor VIIa; Fibrinolysis; | 2007 |
DDAVP and tranexamic acid for dental extractions in a mild haemophiliac.
Topics: Adult; Arginine Vasopressin; Cyclohexanecarboxylic Acids; Deamino Arginine Vasopressin; Dental Care | 1984 |
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
Topics: Adolescent; Antigens; Child; Factor VII; Factor VIIa; Factor VIII; Hemophilia A; Humans; Isoantibodi | 1983 |
Repair of a cleft palate in a child with hemophilia A.
Topics: Child, Preschool; Cleft Palate; Dose-Response Relationship, Drug; Factor VIII; Hemophilia A; Hemosta | 1983 |
[A case of acquired hemophilia].
Topics: Aged; Blood Transfusion; Erythrocyte Transfusion; Factor VIII; Female; Hemophilia A; Humans; Tranexa | 1984 |
Adenotonsillectomy in patients with inherited bleeding disorders.
Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F | 1993 |
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases.
Topics: Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Factor VIIa; Factor VIII; Hemophilia A; | 2000 |
Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A.
Topics: Acute Disease; Adult; Antifibrinolytic Agents; Hemophilia A; Humans; Kidney Cortex Necrosis; Male; T | 2001 |
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin; | 2001 |
Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage.
Topics: Adult; Autoantibodies; Deamino Arginine Vasopressin; Factor VIII; Female; Hemophilia A; Hemostatics; | 2002 |
DDAVP and cryoprecipitate in mild haemophilia.
Topics: Arginine Vasopressin; Blood Preservation; Cryoglobulins; Deamino Arginine Vasopressin; Factor VIII; | 1979 |
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas | 1979 |
Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII.
Topics: Adult; Dental Care; Factor VIIa; Factor VIII; Hemophilia A; Hemostasis; Humans; Male; Recombinant Pr | 1991 |
Topical aminocaproic acid in hemophiliac patients undergoing dental extraction.
Topics: Administration, Oral; Administration, Topical; Aminocaproates; Hemophilia A; Humans; Injections, Int | 1990 |
Management of oral bleeding in haemophilic patients.
Topics: Aprotinin; Cyclohexanecarboxylic Acids; Drug Combinations; Factor XIII; Fibrin Tissue Adhesive; Fibr | 1988 |
Management of oral bleeding in haemophilic patients.
Topics: Aprotinin; Drug Combinations; Drug Therapy, Combination; Factor XIII; Fibrin Tissue Adhesive; Fibrin | 1989 |
Management of oral bleeding in haemophilic patients.
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemostasis; Humans; Mouthwashes; Oral Hemorrhage; Tranexa | 1988 |
Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery.
Topics: Administration, Oral; Administration, Topical; Cyclohexanecarboxylic Acids; Dental Care for Disabled | 1986 |
An alternative to blood product therapy for dental extractions in the mild to moderate haemophiliac patient.
Topics: Adult; Cyclohexanecarboxylic Acids; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophil | 1987 |
Control of gingival hemorrhage in hemophilic patients by inhibition of fibrinolysis with tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Fibri | 1988 |
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo | 1988 |
Treatment of bilateral fracture of the mandible in a hemophilic patient with inhibitor to factor VIII.
Topics: Adult; Blood Coagulation Factors; Factor VIII; Fracture Fixation; Hemophilia A; Humans; Male; Mandib | 1987 |
Dental extractions in hemophilia: reflections on 10 years' experience.
Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII; | 1985 |
Tranexamic acid to reduce hemorrhage in hemophiliacs.
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Humans; Oral Hemorrhage; Tranexamic Acid | 1988 |
Oral surgery in hemophiliacs.
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Humans; Mouth; Oral Hemorrhage; Tranexamic Acid | 1987 |
Tranexamic acid.
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemorrhage; Humans; Premedication; Prospective Studies; T | 1987 |